Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia
The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.
• Any gender,
• Adults (\>18 years old),
• New suspect diagnosis of acute myeloid leukemia (ELN2022 Criteria)
• Capable of comprehend the study and the consent form,
• Willing to sign the informed consent for the study.
⁃ For the retrospective population we will select:
⁃ biological samples (BM Biopsies, BM Aspirates and PB) already banked upon research purpose informed consent and collected from the 01/06/2006 up to 01/06/2024 from adults patients with diagnosis of acute myeloid leukemia according to ELN2017 Criteria.